Why your team thinks carefully before starting an antibioticBakit mag-isip nang mabuti ang inyong team bago simulan ang antibiotikoNganong mag-hunahuna og maayo ang inyong team una mosugod og antibiotikoBakit mag-isip a masalese ing team mu bayu magumpisa ning antibiotiko
Antibiotics kill bacteria. They do nothing for a viral cold, and they do nothing for the muscle soreness that sometimes follows a hard dialysis session. Every time an antibiotic is used when it is not truly needed — or the wrong one is chosen — the bacteria that survive have a chance to learn how to resist it. That resistance does not stay with one person; it can spread to other patients in the same unit, through the same staff hands, the same shared machines, the same environment.Pinapatay ng antibiotiko ang bakterya. Wala itong magagawa sa sipon na dulot ng virus, at wala rin itong magagawa sa pananakit ng kalamnan na minsan sumusunod sa mahirap na sesyon ng dialysis. Sa tuwing ginagamit ang antibiotiko kahit hindi talaga kailangan — o mali ang napiling gamot — nagkakaroon ng pagkakataon ang mga bakteryang nabubuhay na matutong lumaban dito. Hindi lamang sa isang tao nananatili ang paglaban na ito; maaari itong kumalat sa ibang pasyente sa parehong unit, sa parehong kamay ng staff, sa parehong shared na makina, sa parehong kapaligiran.Ang antibiotiko mopatay sa bakterya. Wala kini sulbara sa sip-on nga hinungdan sa virus, ug wala usab kini sulbara sa kasakit sa unod nga usahay mosunod sa lisod nga sesyon sa dialysis. Sa matag higayon nga gigamit ang antibiotiko bisan wala kini gikinahanglan — o sayop ang gipili nga tambal — naay higayon ang mga bakteryang nabuhi nga makat-on kon unsaon pagbatok niini. Kini nga pagbatok dili lang magpabilin sa usa ka tawo; mahimo kining mokaylap sa ubang pasyente sa parehas nga unit, pinaagi sa parehas nga kamot sa staff, parehas nga gigamit nga makina, parehas nga palibot.Papatayan ne ning antibiotiko ing bakterya. Ala yang gagawan king sipon a gagawa ning virus, at ala yang gagawan king kirat ning laman a maminsan sumusunud king mabigat a sesyon ning dialysis. King balang isipan ing antibiotiko istung ali ya talaga kailangan — o mali ing pinili a gamut — mika-ubra deng bakteryang mibie a manaral makilaban kaniti. Ing pamanlaban a ini, e ya papanatili king metung mu lang tau; mibulus ya makapunta karing aliwang pasyente king parehung unit, king parehung gamat ning staff, parehung makina, parehung kapaligiran.
Patients on hemodialysis are especially exposed. A catheter that connects directly to the bloodstream, three sessions a week that bring you into a shared clinical space, and a weakened immune system all raise the chance of infection — and of the wrong antibiotic decision. Antibiotic stewardship is simply the discipline of using the right drug, at the right dose, for the right length of time, only when there is a real infection to treat. It protects you today, and it protects the antibiotics that will still work for you and for other patients next year.Lalong nalalantad ang mga pasyenteng sumasailalim sa hemodialysis. Ang catheter na direktang konektado sa daloy ng dugo, tatlong sesyon kada linggo na nagdadala sa inyo sa isang shared na klinikal na espasyo, at humihinang sistema ng imyunidad — lahat ng ito ay nagpapataas ng posibilidad ng impeksyon — at ng maling desisyon sa antibiotiko. Ang antibiotic stewardship ay ang disiplina lamang ng paggamit ng tamang gamot, sa tamang dosis, sa tamang haba ng panahon, tanging kapag mayroong tunay na impeksyon na dapat gamutin. Pinoprotektahan nito kayo ngayon, at pinoprotektahan din nito ang mga antibiotikong gagana pa rin para sa inyo at sa ibang pasyente sa susunod na taon.Labi na nga naeksponer ang mga pasyente nga nag-hemodialysis. Ang catheter nga direktang konektado sa agos sa dugo, tulo ka sesyon kada semana nga nagdala kaninyo sa usa ka shared nga klinikal nga lugar, ug nagluya nga immune system tanan nagpataas sa tsansa nga mainpeksyon — ug sa sayop nga desisyon sa antibiotiko. Ang antibiotic stewardship mao lang ang disiplina sa paggamit sa tama nga tambal, sa tama nga dosis, sa tama nga gidugayon, kung naay tinuod nga impeksyon nga tambalan. Kini manalipod kaninyo karon, ug manalipod usab sa mga antibiotiko nga molihok pa gihapon alang kaninyo ug sa ubang pasyente sa sunod tuig.Mas maalua deng pasyenteng manibaan king hemodialysis. Ing catheter a direkta yang konektadu king dalan ning daya, atlung sesyon king metung a lingu a mikuk kekayu king metung a shared a klinikal a lugal, at ing malussang sistema ning imyunidad, sablang ini mikapataas la king pamibiye ning impeksyon — at ning mali a desisyon king antibiotiko. Ing antibiotic stewardship iya mu ing disiplina king pamanggamit king tamang gamut, king tamang dosis, king tamang kalabasan a panaun, istung atin yang tune a impeksyong pilan gamutan. Iyang pipanatilian ka ngeni, at pipanatilian na naman deng antibiotikung gumana pa para keka at karing aliwang pasyente king mumuli a banua.
The idea in one sentenceAng ideya sa isang pangungusapAng ideya sa usa ka tudlingIng ideya king metung a sentence
A blood culture drawn before your first dose, a specific antibiotic timed around your dialysis schedule, and a check-in 2–3 days later to confirm the drug is still the right one — that sequence is what keeps antibiotics working, for you and for everyone who dialyzes after you.Ang blood culture na kinuha bago ang unang dosis, ang tiyak na antibiotikong naka-timing sa inyong dialysis schedule, at ang pagsusuri 2–3 araw makalipas upang kumpirmahin na tama pa rin ang gamot — ang sunod-sunod na iyon ang nagpapanatili sa antibiotiko na gumagana, para sa inyo at para sa lahat ng magda-dialysis pagkatapos ninyo.Ang blood culture nga gikuha una sa una nga dosis, ang piho nga antibiotiko nga gi-timing sa inyong dialysis schedule, ug ang pag-check 2–3 ka adlaw human aron makumpirma nga tama gihapon ang tambal — kana nga sunod-sunod mao ang nagpahimutang sa antibiotiko nga molihok, alang kaninyo ug sa tanan nga mo-dialysis human kaninyo.Ing blood culture a mikua bayu ing anggang dosis, ing espesipikung antibiotiku a me-timing king dialysis schedule mu, at ing pamanuri 2–3 aldo kaibat ban ipakilala king tama ya pa ing gamut — iyan a sunud-sunod ing mikatpanatili king antibiotiku a gumagana, para keka at para karing anggang miki-dialysis kaibat mu.
Fever or chills during dialysis — what it can meanLagnat o panginginig sa panahon ng dialysis — ano ang maaaring ibig sabihin nitoHilanat o pagkurog panahon sa dialysis — unsa ang mahimong ipasabot niiniLagnat o panginginig kabang dialysis — nanu ing misabi na iti
Every hemodialysis session pulls your blood out through an access — a catheter, a fistula, or a graft — runs it through the dialyzer, and returns it. If bacteria have entered through that access, dialysis can circulate them through your whole bloodstream in minutes. A new fever, shaking chills, or a sudden drop in blood pressure during or right after a session is your body's alarm that bacteria may be in the blood, not just on the skin.Sa bawat sesyon ng hemodialysis, hinuhugot ang inyong dugo sa pamamagitan ng access — isang catheter, fistula, o graft — dinadaan sa dialyzer, at ibinabalik. Kung may bakteryang pumasok sa access na iyon, maaaring ikalat ito ng dialysis sa buong daloy ng inyong dugo sa loob ng ilang minuto. Ang bagong lagnat, panginginig, o biglaang pagbaba ng blood pressure sa panahon o kaagad pagkatapos ng sesyon ay senyales ng inyong katawan na maaaring may bakterya sa dugo, hindi lamang sa balat.Sa matag sesyon sa hemodialysis, gikuha ang inyong dugo pinaagi sa access — usa ka catheter, fistula, o graft — gipaagi sa dialyzer, ug gibalik. Kung naay bakterya nga misulod niana nga access, mahimong ipakaylap kini sa dialysis sa tibuok agos sa inyong dugo sulod sa pipila ka minuto. Ang bag-ong hilanat, pagkurog, o kalit nga pagkanaog sa blood pressure panahon o dayon human sa sesyon usa ka senyales sa inyong lawas nga tingali naay bakterya sa dugo, dili lang sa panit.King balang sesyon ning hemodialysis, ikukua ing daya mu king access — metung a catheter, fistula, o graft — ipapalabas king dialyzer, at ipapawali. Istung atin yang bakteryang mekalub king access a ita, mibulus yang ikalat ning dialysis king mabilis a oras king mabilug a dalan ning daya mu. Ing bayung lagnat, panginginig, o biglang pamanaba ning presyon ning daya kabang o milabas kapa king sesyon, iya yang senyas ning katawan mu a mika-ubra bakteryang atiu king daya, e mu king balat.
How bacteria on a dialysis catheter can reach the bloodstream: bacteria enter at the skin exit site, travel along the catheter surface into the vein, and are then circulated through the whole body as dialysis moves blood out and back.
The most common entry point in people who dialyze through a catheter is the catheter itself — where it exits the skin, or the internal channel it sits in. Fistulas and grafts are safer but can also become infected, usually with warmth, swelling, redness, or pain over the access. Fever is not always from the access, though; it can come from the lungs, the urinary tract, the skin, or elsewhere. That is exactly why the next step is not “start an antibiotic” — it is “find the source.”Ang pinakakaraniwang pinasukan sa mga taong nagda-dialysis gamit ang catheter ay ang mismong catheter — kung saan ito lumalabas sa balat, o ang panloob na landas na kinaroroonan nito. Mas ligtas ang mga fistula at graft ngunit maaari ring mainpeksyon, karaniwang may init, pamamaga, pamumula, o sakit sa access. Ngunit hindi laging galing sa access ang lagnat; maaari itong manggaling sa baga, urinary tract, balat, o iba pa. Kaya naman hindi ang susunod na hakbang ay “magsimula ng antibiotiko” — kundi “hanapin ang pinagmulan.”Ang kasagarang gisudlan sa mga tawo nga nag-dialysis pinaagi sa catheter mao ang mismong catheter — asa kini mogawas sa panit, o sa sulod nga agianan diin kini nahimutang. Mas luwas ang fistula ug graft apan mahimo usab kining mainpeksyon, kasagaran adunay init, paghubag, pagpula, o kasakit sa access. Apan dili kanunay gikan sa access ang hilanat; mahimo kining gikan sa baga, urinary tract, panit, o uban pa. Mao gyud nga ang sunod nga lakang dili “sugdi ang antibiotiko” — kondili “pangitaon ang gigikanan.”Ing pekakaraniwan a kekalub karing taung mag-dialysis king catheter iya ing mismung catheter — nokarin ya lalabas king balat, o ing kaladaladan a alagwan na. Mas mapanatag deng fistula at graft dapot mibulus mu naman lang mainpeksyon, karaniwan atin yang init, pamamaga, pamumula, o sakit king access. Alimbawa, ali lagi king access ing lagnat; mibulus yang mikawani king baga, urinary tract, balat, o aliwa pa. Iya ita ing dake at ing tuki a hakbang ali ya “magumpisa king antibiotiko” — nung e ita, “anapan ing pikuanan.”
Other infections your dialysis team watches forIbang impeksyon na binabantayan ng inyong dialysis teamUbang impeksyon nga gibantayan sa inyong dialysis teamAliwang impeksyon a bibantaian ning dialysis team mu
Not every fever comes from your catheter or fistula. Three other infections come up often in people on dialysis: chest infections (including tuberculosis, which is far more common in the Philippines than in most other countries), urinary tract infections (even if you make little or no urine), and skin infections — especially if you have diabetes, or a cut or wound that is slow to heal. Each one needs its own kind of test and its own treatment, so telling your team exactly what you are feeling helps them look in the right place first.Hindi lahat ng lagnat ay nanggagaling sa inyong catheter o fistula. May tatlo pang impeksyon na madalas lumitaw sa mga taong nagda-dialysis: impeksyon sa dibdib (kasama ang tuberculosis, na mas karaniwan sa Pilipinas kaysa sa karamihan ng ibang bansa), impeksyon sa urinary tract (kahit kaunti o wala kayong ihi), at impeksyon sa balat — lalo na kung mayroon kayong diyabetis, o isang sugat na mabagal gumaling. Bawat isa ay nangangailangan ng sariling uri ng pagsusuri at paggamot, kaya ang pagsasabi nang eksakto sa inyong team kung ano ang inyong nararamdaman ay tumutulong sa kanila na tumingin sa tamang lugar muna.Dili tanan nga hilanat gikan sa inyong catheter o fistula. Naay tulo pa ka impeksyon nga sagad mahitabo sa mga tawo nga nag-dialysis: impeksyon sa dughan (lakip ang tuberculosis, nga mas komon sa Pilipinas kaysa sa kadaghanan sa ubang nasod), impeksyon sa urinary tract (bisan gamay ra o wala moy ihi), ug impeksyon sa panit — ilabina kon naa moy diabetes, o samad nga hinay mo-ayo. Ang matag usa nagkinahanglan sa iyang kaugalingong klase sa pagsusi ug tambal, mao nga ang pagsulti nga eksakto sa inyong team kon unsa ang inyong gibati makatabang kanila nga motan-aw sa husto nga dapit una.Ali sablang lagnat lulwal king catheter o fistula mu. Atin pang atlung impeksyon a maminsan mekit karing taung mag-dialysis: impeksyon king salu (kayabe ne ing tuberculosis, a mas karaniwan king Pilipinas kesa king kadakalan da ring aliwang bansa), impeksyon king urinary tract (agyang ditak o ala kang iki), at impeksyon king balat — lalu na nung atin kang diabetes, o metung a sugat a matagalan gumaling. Balang metung kailangan ne ing sariling uri ning pamanuri at pamagamut, kanita ing pamagsabi mu king team mu nu nanu ing rerasa mu tutulung karela a lawan da ing tamang lugal anti.
Three infection sources beyond the dialysis access that your care team watches for: chest and lung infections (including tuberculosis), urinary tract infections, and skin or wound infections.
Chest & lungsDibdib at bagaDughan ug bagaSalu at baga
A cough that will not go away, night sweats, or unexplained weight loss can be signs of tuberculosis (TB) or pneumonia. Both need chest imaging and a specific test, not an antibiotic guess.Ang ubo na hindi nawawala, pagpawis sa gabi, o hindi maipaliwanag na pagbaba ng timbang ay maaaring senyales ng tuberculosis (TB) o pulmonya. Pareho itong nangangailangan ng chest imaging at tiyak na pagsusuri, hindi hula na antibiotiko.Ang ubo nga dili mawala, pagpanglaya sa gabii, o dili maipatin-aw nga pagkunhod sa gibug-aton mahimong senyales sa tuberculosis (TB) o pneumonia. Managsama kining nagkinahanglan og chest imaging ug piho nga pagsusi, dili hunahuna nga antibiotiko.Ing ubu a e mawala, pamaglaya king bengi, o e maipaliwanag a pamanaba ning timbang mibulus lang senyas ning tuberculosis (TB) o pulmonya. Kaduang ini kailangan la ning chest imaging at espesipikung pamanuri, e hula a antibiotiko.
Urinary tractUrinary tractUrinary tractUrinary tract
Pain or burning when urinating, or fever with no other cause, can point to a urinary tract infection — even in people who make very little urine, since the native kidneys and bladder are still there.Ang sakit o pagkasunog kapag umiihi, o lagnat na walang ibang dahilan, ay maaaring senyales ng impeksyon sa urinary tract — kahit sa mga taong kaunti lamang ang iniihi, dahil naroon pa rin ang orihinal na bato at pantog.Ang kasakit o kasunog kon mangihi, o hilanat nga walay laing hinungdan, mahimong senyales sa impeksyon sa urinary tract — bisan sa mga tawo nga gamay ra kaayo ang ihi, tungod kay naa pa gihapon ang orihinal nga kidney ug bladder.Ing sakit o pamanyulu istung mikiki, o lagnat a alang aliwang dake, mibulus lang senyas ning impeksyon king urinary tract — agyang karing taung ditak mu ing kikian da, uling atiu pa ing orihinal a bato at pantog.
Skin & woundsBalat at sugatPanit ug samadBalat at sugat
A wound, cut, or foot sore that is red, warm, swollen, or draining needs to be looked at — especially with diabetes, since healing is slower and infection can spread faster than it looks.Ang sugat, hiwa, o sugat sa paa na pula, mainit, namamaga, o may lumalabas na likido ay kailangang tingnan — lalo na kung mayroong diyabetis, dahil mas mabagal ang paggaling at maaaring kumalat nang mas mabilis ang impeksyon kaysa sa hitsura nito.Ang samad, gilok, o samad sa tiil nga pula, init, hubag, o may nagagawas nga likido kinahanglan susihon — ilabina kon naa diabetes, tungod kay hinay ang pag-ayo ug mahimong mokaylap nga mas paspas ang impeksyon kaysa sa dagway niini.Ing sugat, gilis, o sugat king bitis a mapula, maninap, mamaga, o atin yang lulwal a likido kailangan lawan — lalu na nung atin kang diabetes, uling matagalan ing pamagaling at mibulus yang mikakalat mas mabilis ing impeksyon kesa king itsura na.
These are covered in more depth in two related guides: Tuberculosis and Kidney Disease and The Native Kidney in the Anuric Dialysis Patient.Ang mga ito ay tinatalakay nang mas malalim sa dalawang kaugnay na gabay: Tuberculosis at Sakit sa Bato at Ang Orihinal na Bato sa Pasyenteng Anuric na Nagda-dialysis.Kini gihisgotan nga mas lawom sa duha ka may kalabotan nga giya: Tuberculosis ug Sakit sa Kidney ug Ang Orihinal nga Kidney sa Anuric nga Pasyenteng Nag-dialysis.Deting bage tatalakayan lalam king aduang kaugnay a gabay: Tuberculosis at Sakit king Bato at Ing Orihinal a Bato king Pasyenteng Anuric a Mag-dialysis.
Why blood is drawn before the antibiotic startsBakit kinukuha ang dugo bago simulan ang antibiotikoNganong gikuha ang dugo una pa mosugod ang antibiotikoBakit ikukua ing daya bayu magumpisa ing antibiotiko
A blood culture is a small sample of your blood placed in a bottle designed to let any bacteria in it grow, so the laboratory can identify exactly which organism is present and which antibiotics kill it. Once even one dose of antibiotic has been given, the sample is far less likely to grow anything — the drug suppresses the bacteria in the bottle just as it does in your body. A culture drawn afterward often comes back falsely “clean,” even though the infection is real.Ang blood culture ay maliit na sample ng inyong dugo na inilalagay sa isang bote na dinisenyo upang bigyang-daan ang anumang bakterya na lumaki, upang matukoy ng laboratoryo kung anong eksaktong organismo ang naroroon at kung anong mga antibiotiko ang pumapatay dito. Kapag naibigay na kahit isang dosis ng antibiotiko, mas malamang na wala nang lalaki sa sample — sinusupress ng gamot ang bakterya sa bote tulad ng ginagawa nito sa inyong katawan. Ang culture na kinuha pagkatapos ay kadalasang “malinis” ang resulta kahit totoo ang impeksyon.Ang blood culture usa ka gamay nga sample sa inyong dugo nga gibutang sa botelya nga gidisenyo aron pahimuslan ang bisan unsang bakterya nga motubo, aron mahibal-an sa laboratoryo kon unsa gyud nga organismo ang naa ug unsang antibiotiko ang mopatay niini. Sa higayon nga nahatag na bisan usa ka dosis sa antibiotiko, mas dako ang tsansa nga wala nay motubo sa sample — gipugngan sa tambal ang bakterya sa botelya sama sa ginahimo niini sa inyong lawas. Ang culture nga gikuha human niini kasagaran mobalik og “limpyo” nga resulta bisan tinuod ang impeksyon.Ing blood culture, metung yang malating sample ning daya mu a ipapalub king metung a bote a dinisenyu ban pabilan ing baling bakteryang atin king dinan a mekit, ban abalu ne ning laboratoryo nu ing eksaktung organismong atiu at nu ring antibiotikung mamate kaniti. King metung mung ibié dosis ning antibiotiko, mas mala-ala keng ala nang mekit king sample — sinasugpu ne ning gamut ing bakterya king bote a singkat kaya na ing gagawan na king katawan mu. Ing culture a mikua kaibat balamu ing resulta na “malinis” agyang tune ing impeksyon.
This is why your nurse or doctor draws blood cultures — usually from two separate sites — before the first antibiotic dose whenever that is safely possible. It costs a few extra minutes. It does not delay treatment if you are seriously unwell; in that situation, cultures are drawn quickly and the first antibiotic dose still follows without waiting for results. What it buys you is a laboratory answer, 24–72 hours later, that lets your team switch from a broad “best guess” drug to the exact one your infection needs — or stop the antibiotic altogether if no true infection is found.Kaya naman kumukuha ng blood cultures ang inyong nurse o doktor — karaniwang mula sa dalawang magkaibang lugar — bago ang unang dosis ng antibiotiko sa tuwing ligtas itong gawin. Ilang minuto lamang ang gastos nito. Hindi nito inaantala ang paggamot kung malubha kayong may sakit; sa ganoong sitwasyon, mabilis na kinukuha ang mga culture at sumusunod pa rin ang unang dosis ng antibiotiko nang hindi hinihintay ang resulta. Ang ibinibigay nito sa inyo ay isang sagot mula sa laboratoryo, 24–72 oras ang tagal, na nagpapahintulot sa inyong team na lumipat mula sa malawak na “pinakamahusay na hula” na gamot patungo sa eksaktong kailangan ng inyong impeksyon — o ihinto ang antibiotiko kung wala palang tunay na impeksyon na natagpuan.Mao nga mokuha og blood cultures ang inyong nars o doktor — kasagaran gikan sa duha ka lain-laing dapit — una pa sa una nga dosis sa antibiotiko sa dihang luwas kining buhaton. Pipila lang ka minuto ang gasto niini. Dili niini malangan ang tambal kon grabe na mo og sakit; niana nga kahimtang, dali rang kuhaon ang mga culture ug mosunod gihapon ang una nga dosis sa antibiotiko nga wala maghulat sa resulta. Ang gihatag niini kaninyo mao ang tubag gikan sa laboratoryo, 24–72 ka oras ang gidugayon, nga motugot sa inyong team nga mobalhin gikan sa lapad nga “labing maayong hunahuna” nga tambal ngadto sa eksaktong gikinahanglan sa inyong impeksyon — o ihunong ang antibiotiko kon walay tinuod nga impeksyon nga nakit-an.Iya ita ing bakit mikua deng blood cultures ing nurse o doktor mu — karaniwan king aduang mibulang lugal — bayu ing anggang dosis ning antibiotiko king oras a mapanatag yang gawan iti. Aduang minutu mu ing agad na. Ali ne ipapaulit ing pamagamut istung mabyasa kang masakit; king ganitang kalagayan, mabilis lang kinukua deng culture at sundan yapin ing anggang dosis ning antibiotiko a e me hihinintay ing resulta. Ing ibibie na keka iyang metung a simbag manibat king laboratoryo, 24–72 oras ing kalabasan, a mangapasibayu king team mu a mikawani king malapad a “pekamayap a hula” a gamut paknuan king eksaktung kailangan ning impeksyon mu — o ipaulit ing antibiotiko istung ala yang tune a impeksyon a mekit.
Antibiotics and your dialysis scheduleAntibiotiko at ang inyong dialysis scheduleAntibiotiko ug ang inyong dialysis scheduleAntibiotiko at ing dialysis schedule mu
Most drugs leave the body through the kidneys. Yours no longer clear medication the way healthy kidneys do — and dialysis itself can pull some antibiotics straight out of your blood along with the toxins it is designed to remove. That means the dose, and sometimes even the choice of drug, has to be built around your specific dialysis schedule: how many sessions a week, how long each one runs, and whether the drug is one dialysis removes easily or one it barely touches.Karamihan sa mga gamot ay umaalis sa katawan sa pamamagitan ng bato. Ang inyo ay hindi na nag-aalis ng gamot sa paraang ginagawa ng malusog na bato — at ang dialysis mismo ay maaaring hugutin ang ilang antibiotiko nang tuwiran mula sa inyong dugo kasabay ng mga lason na dinisenyo nitong alisin. Ibig sabihin, ang dosis, at kung minsan pati ang pagpili ng gamot, ay dapat itayo sa paligid ng inyong tiyak na dialysis schedule: ilang sesyon kada linggo, gaano katagal ang bawat isa, at kung ang gamot ay isang uri na madaling inaalis ng dialysis o halos hindi nito nagagalaw.Kadaghanan sa mga tambal mogawas sa lawas pinaagi sa kidney. Ang inyoha dili na mikuha og tambal sa paagi nga ginabuhat sa himsog nga kidney — ug ang dialysis mismo mahimong mokuha sa pipila ka antibiotiko direkta gikan sa inyong dugo uban sa mga hilo nga gidisenyo niini nga tangtangon. Kana nagpasabot nga ang dosis, ug usahay bisan ang pagpili sa tambal, kinahanglan itukod libot sa inyong piho nga dialysis schedule: pila ka sesyon kada semana, hangtod asa ka dugay ang matag usa, ug kon ang tambal usa ka klase nga dali kuhaon sa dialysis o halos wala gyud nahikapa niini.Kaburiananan da ring gamut lulwal king katawan king kabang ning bato. Ing keka ali ne mikwa ning gamut king paralan a gagawan na ning malusug a bato — at ing dialysis mismu mibulus yang ikua deng aliwang antibiotiko direkta manibat king daya mu, kasabay da ring lasun a dinisenyu nang ilako. Kalaguan na iti a ing dosis, at maminsan ing pamipili king gamut, dapat metung yang itayad libut king espesipiku a dialysis schedule mu: pilan sesyon king metung a lingu, makananu kalambat ing balang metung, at nung ing gamut metung yang uri a madalis alaan na ning dialysis o meya yang alilan.
This is why some antibiotics are given as an injection right at the end of a dialysis session rather than daily at home — giving the dose after your blood has already been filtered means it is not filtered right back out, and it saves you an extra clinic visit. Your nephrologist, dialysis nurse, or pharmacist should be able to tell you exactly when your antibiotic is timed relative to your sessions and why. If your dialysis schedule changes for any reason — a missed session, a holiday, a rescheduled slot — tell the team giving your antibiotic immediately, because the timing plan may need to change with it.Kaya naman ang ilang antibiotiko ay ibinibigay bilang iniksyon sa pagtatapos mismo ng sesyon ng dialysis sa halip na araw-araw sa bahay — ang pagbibigay ng dosis matapos na masala na ang inyong dugo ay nangangahulugang hindi na ito agad masasala palabas, at nakakatipid ito ng dagdag na bisita sa klinika. Dapat masasabi sa inyo ng inyong nephrologist, dialysis nurse, o pharmacist kung kailan eksaktong naka-timing ang inyong antibiotiko kaugnay sa inyong mga sesyon at kung bakit. Kung magbago ang inyong dialysis schedule sa anumang kadahilanan — nakaligtaang sesyon, holiday, na-reschedule na slot — sabihin agad sa team na nagbibigay ng inyong antibiotiko, dahil maaaring kailangang magbago rin ang plano sa timing.Mao nga ang pipila ka antibiotiko gihatag isip inject sa hangtod gyud sa sesyon sa dialysis inay adlaw-adlaw sa balay — ang paghatag sa dosis human na masala ang inyong dugo nagpasabot nga dili na kini dayon masala pagawas, ug makatipid kini og dugang bisita sa klinika. Angay makasulti kaninyo ang inyong nephrologist, dialysis nars, o parmasyutiko kon kanus-a eksakto naka-timing ang inyong antibiotiko may kalabotan sa inyong mga sesyon ug ngano. Kon mausab ang inyong dialysis schedule sa bisan unsang hinungdan — nawala nga sesyon, holiday, na-reschedule nga slot — sultihi dayon ang team nga naghatag sa inyong antibiotiko, tungod kay basin kinahanglan usbon usab ang plano sa timing.Iya ita ing bakit deng arang antibiotiko ibibie lang metung a iniksiyon king pamamalintuad na ning sesyon ning dialysis kesa king aldo-aldo king bale — ing pamibie king dosis kaibat mesalang ing daya mu misabi ya a e ne agad mesalang lulwal, at makatipid ka pa king dagdag a bisita king klinika. Dapat asabi da keka ning nephrologist, dialysis nurse, o pharmacist mu nu kailan me-timing ing antibiotiko muanti king sesyon mu at nu bakit. Nung mibayu ing dialysis schedule mu king baling dake — migsala a sesyon, holiday, na-reschedule a slot — sabian mu agad king team a mamibie king antibiotiko mu, uling mibulus yang kailangan mibayu ing plano king timing.
The 48–72-hour check-inAng 48–72-oras na pagsusuriAng 48–72-ka-oras nga pag-checkIng 48–72-oras a pamanuri
The first antibiotic you receive is almost always a “best guess” chosen to cover the most likely bacteria for your situation, before the culture results are back. Two to three days later, your doctor deliberately revisits that decision — this is called an antibiotic timeout. Are you clinically better? What did the culture grow? Is a narrower, more targeted drug now possible? Should the antibiotic switch from an IV to a pill? Does it need to continue at all?Ang unang antibiotikong natatanggap ninyo ay halos palaging isang “pinakamahusay na hula” na pinili upang saklawin ang pinakamalamang na bakterya para sa inyong sitwasyon, bago pa bumalik ang resulta ng culture. Dalawa hanggang tatlong araw pagkatapos, sinasadyang binabalikan ng inyong doktor ang desisyong iyon — tinatawag itong antibiotic timeout. Mas maganda na ba ang klinikal na kalagayan ninyo? Ano ang lumaki sa culture? Posible na bang gumamit ng mas makitid, mas target na gamot? Dapat bang lumipat ang antibiotiko mula IV patungo sa tableta? Kailangan pa ba talagang ipagpatuloy?Ang una nga antibiotiko nga inyong madawat halos kanunay usa ka “labing maayong hunahuna” nga gipili aron matabunan ang labing posible nga bakterya para sa inyong kahimtang, sa dili pa mobalik ang resulta sa culture. Duha hangtod tulo ka adlaw human niini, tinuyo nga balikan sa inyong doktor kana nga desisyon — gitawag kining antibiotic timeout. Mas maayo na ba ang inyong klinikal nga kahimtang? Unsa ang mitubo sa culture? Posible na ba karon ang mas pig-ot, mas target nga tambal? Angay bang mobalhin ang antibiotiko gikan sa IV ngadto sa tableta? Kinahanglan pa ba gyud kini ipadayon?Ing anggang antibiotikung atanggap yu, malage-lagi yang metung a “pekamayap a hula” a pinili ban matakupan ing pekamala-ala a bakterya para king kalagayan mu, bayu pa mawali ing resulta ning culture. Adua anggang atlung aldo kaibat na, sinadya nang babalikan ning doktor mu ing desisyon a ita — tatawagan yang antibiotic timeout. Mayap ne ba ing klinikal a kalagayan mu? Nanu ing mekit king culture? Mibulus ne ba ngeni ing pamanggamit ning masikip, mas target a gamut? Dapat ne ba mikawani ing antibiotiko king IV paknuan king tableta? Kailangan ne ba talaga ipatuloy?
A change at this point is a good sign, not a mistakeAng pagbabago sa puntong ito ay magandang senyales, hindi pagkakamaliAng pag-usab niini nga punto usa ka maayong senyales, dili sayopIng pamibayu king puntung ini, mayap yang senyas, ali ya kamalian
If your antibiotic changes, gets narrowed, or stops after the check-in, that means the plan is working exactly as designed — the team is refining treatment with real information instead of guessing. It is a sign of careful care, not of anything having gone wrong the first time.Kung magbago ang inyong antibiotiko, gawing mas makitid, o ihinto pagkatapos ng pagsusuri, ibig sabihin gumagana ang plano nang eksaktong tulad ng dinisenyo — pinapahusay ng team ang paggamot gamit ang tunay na impormasyon sa halip na paghula. Senyales ito ng maingat na pangangalaga, hindi ng anumang nagkamali sa una.Kon mausab ang inyong antibiotiko, gipig-ot, o gihunong human sa pag-check, kana nagpasabot nga ang plano naglihok gyud sumala sa gidisenyo — gipino sa team ang tambal gamit ang tinuod nga impormasyon inay pagtag-an. Kini usa ka senyales sa maampingon nga pag-atiman, dili sa bisan unsang nasayop sa una.Nung mibayu ing antibiotiko mu, misikip, o migpaulit kaibat ning pamanuri, misabi ya a gumagana ing plano king eksaktung kaya ning pamagdisenyu — iyang pipanibayanan ning team ing pamagamut anti king tune a impormasyon kesa king pamanghula. Metung yang senyas ning maingat a pamangasiwa, e ya senyas na atin yang mikamali king enang instansya.
Protecting your catheter, fistula, or graftPagprotekta sa inyong catheter, fistula, o graftPagpanalipod sa inyong catheter, fistula, o graftPamangalaga king catheter, fistula, o graft mu
Preventing infection is the most powerful form of stewardship, because an infection that never happens never needs an antibiotic at all. A few habits matter more than any single medicine:Ang pag-iwas sa impeksyon ang pinakamalakas na anyo ng stewardship, dahil ang impeksyong hindi kailanman nangyari ay hindi na kailangan ng anumang antibiotiko. May ilang gawi na mas mahalaga kaysa sa anumang iisang gamot:Ang pagpugong sa impeksyon mao ang labing gamhanan nga porma sa stewardship, tungod kay ang impeksyon nga wala gyud mahitabo dili na magkinahanglan og bisan unsang antibiotiko. Pipila ka batasan ang mas hinungdanon kaysa sa bisan unsang usa ka tambal:Ing pamibaben king impeksyon iya ing pekamasikan a anyo ning stewardship, uling ing impeksyong ale meyari, ala neng kailangan a baling antibiotiko. Atin lang piling ugali a mas mayabe kesa king baling metung mung gamut:
Four daily habits that lower infection risk for a dialysis catheter, fistula, or graft: hand hygiene before anyone touches the access, keeping the exit site dry, watching daily for early warning signs, and asking about a plan to move to permanent access.
Hands off, unless cleanHuwag hipuin, maliban kung malinisAyaw hikapa, gawas kon limpyoE gagalawan, maliban nung malinis
Never let anyone touch your catheter without washing their hands and wearing gloves first — including yourself.Huwag hayaan ang sinuman na hawakan ang inyong catheter nang hindi muna naghuhugas ng kamay at nagsusuot ng guwantes — kasama na kayo.Ayaw tugoti ang bisan kinsa nga mohikap sa inyong catheter kon wala pa mohunaw sa kamot ug mosul-ob og guwantes — lakip na kamo.E me pabalan ing baling metung a gagalaw king catheter mu nung ali munang manikas ing gamat na at magsulud ning guwantes — miki ka na naman.
Keep the exit site dryPanatilihing tuyo ang exit siteTipigi nga uga ang exit sitePanatilian a matuyu ing exit site
No swimming or soaking a catheter site. Cover it during a shower as your team instructs, and never remove the dressing yourself.Huwag lumangoy o babaran ang catheter site. Takpan ito habang naliligo ayon sa turo ng inyong team, at huwag kailanman tanggalin mismo ang dressing.Ayaw langoy o ibasa ang catheter site. Taboni kini samtang naligo sumala sa gitudlo sa inyong team, ug ayaw gyud kuhaa mismo ang dressing.E langui o ibase ing catheter site. Takpan me kaibat na mikaligu agpang king turo ning team mu, at e mu talaga ilako ing dressing.
Watch for early signsBantayan ang unang mga senyalesBantayi ang sayo nga mga senyalesBantaian deng maunang senyas
Check your access daily for new redness, warmth, tenderness, swelling, or discharge, and report it before your next session.Suriin ang inyong access araw-araw para sa bagong pamumula, init, sakit, pamamaga, o lumalabas na likido, at ipaalam bago ang susunod na sesyon.Susiha ang inyong access adlaw-adlaw para sa bag-ong kapula, kainit, kasakit, paghubag, o nagagawas nga likido, ug isulti una sa sunod nga sesyon.Suriin me ing access mu aldo-aldo para king bayung pamumula, init, sakit, pamamaga, o lulwal a likido, at ipabalu me bayu ing tuking sesyon.
Ask about catheter reductionMagtanong tungkol sa pagbawas ng catheterPangutan-a bahin sa pagkunhod sa catheterTanong tungkul king pamikuku ning catheter
A fistula or graft carries a much lower infection risk than a catheter. If you still dialyze through a catheter, ask your nephrologist about your plan and timeline to move to permanent access.Mas mababa ang panganib ng impeksyon sa fistula o graft kaysa sa catheter. Kung dumadaan pa rin kayo sa dialysis gamit ang catheter, itanong sa inyong nephrologist ang plano at timeline para lumipat sa permanenteng access.Mas ubos ang risgo sa impeksyon sa fistula o graft kaysa sa catheter. Kon nag-dialysis pa gihapon mo pinaagi sa catheter, pangutan-a ang inyong nephrologist bahin sa plano ug timeline aron mobalhin sa permanenteng access.Mababa ing peligru ning impeksyon king fistula o graft kesa king catheter. Nung miki ka pa rin king dialysis king catheter, tanong me king nephrologist mu ing plano at timeline ban mikawani king permanenteng access.
Warning signs — call or go nowMga babalang senyales — tumawag o pumunta ngayonMga pasidaan nga timailhan — tawag o adto karonDeng senyas ning babala — tawag o magpunta ngeni
Go to the emergency room or call your dialysis center immediately if you have:Pumunta sa emergency room o tumawag agad sa inyong dialysis center kung mayroon kayong:Adto sa emergency room o tawag dayon sa inyong dialysis center kon naa kamoy:Magpunta king emergency room o tawag agad king dialysis center mu nung atin ka:
Fever with shaking chills; confusion or unusual drowsiness; a fast heartbeat with a blood pressure that feels low or you feel faint; redness or pus spreading rapidly around your catheter or fistula; severe pain over your access; or trouble breathing. Sepsis from a dialysis access infection can become life-threatening within hours — do not wait for your next scheduled session.Lagnat na may panginginig; pagkalito o hindi karaniwang antok; mabilis na tibok ng puso na may mababang blood pressure o pakiramdam na hihimatayin; pamumula o nana na mabilis kumakalat sa paligid ng inyong catheter o fistula; matinding sakit sa access ninyo; o hirap sa paghinga. Ang sepsis mula sa impeksyon ng access sa dialysis ay maaaring maging nakamamatay sa loob ng ilang oras — huwag maghintay para sa susunod ninyong naka-iskedyul na sesyon.Hilanat nga adunay pagkurog; pagkalibog o dili kasagarang katulog; paspas nga tibok sa kasingkasing nga adunay ubos nga blood pressure o gibati nga malipong; pagpula o nana nga paspas nga mikaylap libot sa inyong catheter o fistula; grabe nga kasakit sa inyong access; o kalisod sa pagginhawa. Ang sepsis gikan sa impeksyon sa access sa dialysis mahimong makapatay sulod sa pipila ka oras — ayaw paghulat sa inyong sunod nga naka-iskedyul nga sesyon.Lagnat a atin yang panginginig; kalibugan o e karaniwan a antuk; masiglang tibuk ning pusu a atin yang mababang presyon ning daya o mirasa kang mimatal; pamumula o nana a mabilis mikakalat king palibut ning catheter o fistula mu; matinding sakit king access mu; o kasakitan king pamiraralnas. Ing sepsis manibat king impeksyon ning access king dialysis mibulus yang maging mapanganib king bie king pilan a oras — e ka maghintay king sunud a naka-iskedyul a sesyon mu.
Frequently asked questionsMga madalas itanongKasagarang gipangutanaKaburiananan a kutang
The stewardship case in intermittent hemodialysis
Patients on maintenance hemodialysis carry a disproportionate share of outpatient parenteral antibiotic exposure in the surveillance literature, and a meaningful fraction of it lacks a documented indication. The physiologic vulnerability is real; the opportunity to tighten decision-making is equally real.
Why hemodialysis patients are a distinct stewardship population
Every hemodialysis session exposes the vascular access to repeated cannulation or line manipulation, circulates the entire blood volume through an extracorporeal circuit several times, and occurs in a shared clinical space with other immunosuppressed patients. Uremia itself impairs neutrophil function, T-cell responsiveness, and the skin barrier, and interdialytic weight and toxin accumulation add hemodynamic stress on top of it. The result is a population with both a higher baseline infection risk and a lower margin for a wrong empiric choice — and, because treatment is so often started before a diagnosis is confirmed, a population unusually exposed to unnecessary antibiotic pressure.
National dialysis-event surveillance in the United States illustrates the scale of the problem, even though the absolute numbers are not directly transferable to a Philippine unit's case mix or antibiotic availability. In an analysis of National Healthcare Safety Network (NHSN) Dialysis Event data covering 7,278 facilities between 2016 and 2020, 648,410 intravenous antibiotic starts (IVAS) were reported, and 161,317 (25%) were not supported by a positive or collected blood culture, a documented purulence or access-site sign, or an associated clinical symptom — and the unsupported proportion rose from 54% of facilities in 2016 to 73% in 2020, even as total IVAS rates fell by an average of 8.2% per year (Fike et al., 2022). A separate six-year NHSN follow-up for 2020 found a national pooled bloodstream infection (BSI) rate of 0.29 per 100 patient-months overall, ranging from 0.12 for arteriovenous (AV) fistulas to 0.80 for central venous catheters (Keenan et al., 2024) — a roughly sevenfold access-type gradient that is the single most consistent finding across the dialysis infection-prevention literature and the strongest argument for catheter reduction as a stewardship intervention in its own right.
The stewardship-relevant framing
A recent narrative review organizes intermittent hemodialysis antimicrobial stewardship around six coordinated domains: prevention, diagnosis, treatment, education and empowerment, monitoring, and research (Shamas et al., 2024). This guide follows the same logic, translated into a workflow a dialysis-center team can actually run: assess and investigate before treating, select empirically within a governed framework, dose around the dialysis schedule, review deliberately at 48–72 hours, and feed the results back into prevention and local antibiogram data. None of the pathways below substitute for the center's own antimicrobial stewardship (AMS) committee, formulary, and named prescribing authority — they describe the shape the decision-making should take, not a specific drug or dose for an unreviewed patient.
Scope and exclusions
This guide addresses adults on intermittent, in-center hemodialysis. It does not apply to continuous kidney replacement therapy (CKRT), prolonged intermittent renal replacement therapy (PIRRT), peritoneal dialysis, home hemodialysis, or pediatric patients — the pharmacokinetics of drug removal differ enough across these modalities that intermittent-HD dosing intervals should never be extrapolated to them. It is a decision-support and education framework, not a substitute for the center's approved empiric protocols, formulary, antibiogram, or infectious-disease/AMS pharmacist consultation, and it is not a sepsis-management protocol — suspected sepsis or hemodynamic instability is managed per the unit's emergency pathway first, without waiting on any stewardship step below.
Diagnostic stewardship before the first dose
Diagnostic stewardship is the discipline of obtaining the right specimen, from the right site, at the right time — before antimicrobial pressure makes that specimen uninterpretable. In a stable patient, this step costs minutes and changes the entire trajectory of therapy; in an unstable patient, it must never delay source control or the first antibiotic dose.
The diagnostic-stewardship and empiric-selection pathway: unstable patients go straight to the emergency pathway; stable patients get paired blood cultures and an access exam before the first antibiotic dose, and empiric selection is built from four inputs — syndrome and severity, the local antibiogram (or a labeled Antimicrobial Resistance Surveillance Program, ARSP, fallback), allergy history, and Access, Watch, Reserve (AWaRe) category and formulary status.
- MDRO
- Multidrug-resistant organism
- ARSP
- Antimicrobial Resistance Surveillance Program
- AWaRe
- Access, Watch, Reserve — the World Health Organization's antibiotic classification framework
Interpretation still requires clinical judgment: a single positive culture growing a common skin commensal (e.g., coagulase-negative staphylococci) in a patient without systemic signs is more likely a contaminant than in a patient with concordant fever, chills, and access findings. Do not let a positive culture alone override a benign clinical picture, and do not let a reassuring culture alone override a convincing clinical picture — correlate, and repeat testing when the two disagree rather than defaulting to either extreme.
Common non-access infection sources in the Philippine dialysis population
Step 4 of the diagnostic-stewardship algorithm above says to look beyond the access before anchoring on it as the default source. In a Philippine dialysis unit, three non-access syndromes come up often enough, and carry distinct enough workups, to warrant their own stewardship considerations rather than being folded into the access-infection pathway by default.
Respiratory infection, including tuberculosis
The Philippines remains among the countries with the highest tuberculosis (TB) burden worldwide, ranking third globally by absolute case count, with an estimated national incidence in the range of several hundred cases per 100,000 population (World Health Organization, 2024). Hemodialysis patients carry additional TB risk on top of that national burden: uremia impairs cell-mediated immunity in a pattern that favors reactivation of latent infection, and the shared indoor space of a dialysis unit itself is a plausible transmission setting when an undiagnosed case is present. A new or worsening cough, low-grade fever, night sweats, or unexplained weight loss should prompt TB evaluation (sputum smear/GeneXpert and chest imaging) run in parallel with, not instead of, the access-focused workup — see this site's dedicated guide to tuberculosis in kidney disease for the full diagnostic and dosing-adjustment pathway. Pneumonia in general is also more frequent and can be more severe in the uremic population, and hemodialysis patients acquire it from both directions: community-acquired pneumonia (CAP) from ordinary community exposure, and hospital-acquired or healthcare-associated pneumonia (HAP) from the same frequent healthcare contact — three sessions a week in a shared clinical space, plus a higher rate of hospitalization and skilled-nursing overlap than the general population — that elevates other stewardship risks in this guide. The distinction matters for empiric coverage, not just documentation: HAP carries a materially higher pretest probability of a resistant gram-negative organism or methicillin-resistant Staphylococcus aureus (MRSA) than typical CAP, so empiric decisions should follow the center's own pneumonia protocol for the correct setting (CAP versus HAP), with renal dose adjustment, rather than one default respiratory regimen applied to both.
Urinary tract infection
In a patient with meaningful residual kidney function, urinary tract infection (UTI) can present in the usual way and be worked up accordingly. In an anuric patient, the native kidneys and bladder are still present and still capable of harboring infection — asymptomatic bacteriuria of uncertain significance, pyocystis in a defunctionalized bladder, or an occult native-kidney source for fever of unclear origin are all easy to overlook once urine output has stopped and the reflex assumption becomes "there is no urine, so there can be no UTI." A urine culture is low-yield and difficult to interpret in a truly anuric patient; correlate with the clinical picture before ordering one reflexively, and see this site's dedicated guide to the native kidney in the anuric dialysis patient for the full diagnostic pathway.
Skin and soft-tissue infection
Diabetes is a leading cause of chronic kidney failure in the Philippines, and the same peripheral vascular disease and sensory neuropathy that predispose to diabetic foot ulcers in the general diabetic population predispose hemodialysis patients to cellulitis and soft-tissue infection with no relationship at all to the vascular access. Examine the feet, pressure points, and any chronic wound — not only the access site — in any hemodialysis patient with fever of unclear source, particularly one with diabetes or known peripheral arterial disease.
Once a non-access source is identified and empiric therapy is started, it still passes through the same 48–72-hour timeout discipline described below — a non-access syndrome is not an exception to stewardship, only a different starting point for the diagnostic workup.
Empiric selection framework, not a dose table
This section deliberately withholds a specific drug-and-dose recommendation
An empiric regimen that is safe for one dialysis center is not automatically safe for another — it depends on the center's own antibiogram, formulary, and prescribing governance. Publishing a fixed empiric drug/dose table here would risk it being applied without that local context. Use the framework below to structure the decision, and finalize the actual agent and dose against your center's current, approved protocol and your antimicrobial stewardship pharmacist or physician.
The World Health Organization's Access, Watch, Reserve (AWaRe) framework classifies antibiotics into Access, Watch, and Reserve groups by resistance-driving potential, and is intended as a stewardship lens layered onto local susceptibility data and clinical judgment — not a stand-alone prescribing rule (World Health Organization, 2022). A center-level empiric protocol should sit at the intersection of four inputs, re-derived locally rather than imported wholesale from a different health system:
AccessWatchReserveWhatever agent is selected, the intended duration and an explicit 48–72-hour review date are set at the time of the first order, not left open-ended.
Dialysis-aware administration and therapeutic monitoring
Intermittent hemodialysis is not a single dosing state. The correct interval depends on the fraction of drug cleared by the dialyzer, the drug's volume of distribution and protein binding, the patient's residual kidney function, and the session schedule itself — none of which can be inferred from estimated glomerular filtration rate (eGFR) the way an outpatient renal dose adjustment normally would be. Never reuse a prior dosing plan without confirming the dialysis schedule has not changed; a missed, shortened, or rescheduled session invalidates the timing assumption the regimen was built on.
Thrice-weekly, post-dialysis dosing
For antibiotics that are meaningfully cleared by hemodialysis, dosing timed to follow the dialysis session — rather than a fixed daily interval — keeps peak concentrations after the clearing event and reduces the number of separate infusion encounters a patient needs, an important consideration when the alternative is a peripheral line for outpatient parenteral antimicrobial therapy (OPAT) purely to accommodate a daily schedule. A 2025 clinical review found literature support for thrice-weekly, post-hemodialysis administration of vancomycin, aminoglycosides, and several beta-lactams (cefazolin, ceftazidime, cefepime, ertapenem) and daptomycin, administered through the existing hemodialysis access rather than a separate line (Tsai et al., 2025). Whether a specific drug is an appropriate candidate for this strategy depends on its individual removal characteristics and the indication being treated — confirm against the center's approved reference and pharmacist before applying it to a given patient.
Thrice-weekly, post-dialysis dosing reference
The regimens below are the specific dosing strategies Tsai et al. (2025) proposed after reviewing the available pharmacokinetic and clinical outcome literature for each drug. Regimens are written as the dose given after each of the week's three sessions in order — a higher third dose (for example, 2/2/3 g) reflects the longer 72-hour interdialytic gap that typically follows the third weekly session, not an escalation for severity.
| Antimicrobial | Proposed thrice-weekly, post-HD regimen | Comment |
|---|---|---|
| Cefazolin | 2/2/2 g or 2/2/3 g | The 3-g dose on the third (72-hour interdialytic) session may be considered for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. |
| Ceftazidime | 1/1/2 g or 2/2/3 g | 1/1/2 g for organisms with an MIC ≤ 8 µg/mL; 2/2/3 g for infections due to Pseudomonas aeruginosa. |
| Cefepime | 2/2/2 g | Preferred over the 1/1/1.5 g or 1.5/1.5/2 g regimens reported in smaller studies, since 1.5 g is not a standard vial concentration. |
| Ertapenem | 500/500/500 mg or 1/1/1 g | Evidence is too limited to prefer one regimen over the other for a specific clinical scenario. |
| Meropenem | Not supported | Thrice-weekly dosing data are limited and were associated with unfavorable outcomes in the one cohort studied; use standard renally adjusted hemodialysis dosing instead. |
| Daptomycin | 6/6/9 mg/kg or 8/8/12 mg/kg | 6/6/9 mg/kg for most infections; 8/8/12 mg/kg for infections due to S. aureus. No dosing recommendation exists yet for vancomycin-resistant Enterococcus faecium. |
Read this table as a literature-derived starting point, not a protocol
Tsai et al. (2025) built these regimens mostly from small, single-center pharmacokinetic studies and case series, and explicitly note that none of the reported regimens adjust for patient weight despite most being expressed as fixed doses. Confirm the regimen, the organism's actual susceptibility, and the patient's residual kidney function and weight against the center's approved reference and pharmacist before using any of these doses — this table is a starting point for that conversation, not a substitute for it, and it does not override the center's own empiric-selection governance described above.
Vancomycin: AUC-guided monitoring
The 2020 revised consensus guideline from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists moved vancomycin monitoring away from trough-only measurement and toward an area-under-the-curve-to-minimum-inhibitory-concentration (AUC/MIC) target of 400–600 mg·h/L (assuming a broth microdilution MIC of 1 mg/L) for serious methicillin-resistant Staphylococcus aureus (MRSA) infections, because trough-targeted dosing at the old 15–20 mg/L range was associated with excess nephrotoxicity without a matching gain in efficacy (Rybak et al., 2020). In intermittent hemodialysis, the practical translation is a pre-dialysis (not a fixed 24-hour) level, drawn at a time relative to the infusion and the next session that your laboratory's Bayesian or two-level AUC method specifies; the exact sampling protocol should be set jointly by pharmacy and the laboratory performing the calculation, not improvised at the bedside.
The recurring safety rule
If the patient's dialysis schedule, modality, current weight, or residual kidney function is not confirmed, or the drug's removal characteristics for the modality in use are not known, do not default to a dose — escalate to the covering pharmacist or prescriber. A wrong assumption about dialyzability is corrected far more easily before the dose is given than after.
The 48–72-hour antibiotic timeout
A deliberate, scheduled reassessment at 48–72 hours is the single highest-yield stewardship intervention after the initial diagnostic workup, because it is the point at which culture data, clinical trajectory, and source-control status are all simultaneously available for the first time. It should be a standing expectation on every antibiotic order, not an occasional audit.
The 48–72-hour antibiotic timeout: reassess the diagnosis, narrow to the culture result, confirm source control, consider an IV-to-oral switch, and set a stop date — escalating to infectious disease or nephrology consultation if bacteremia persists or a metastatic focus is found.
The output of every timeout is one of: stop, continue unchanged, narrow, change agent, change route, change dose or timing, or consult/transfer — recorded with the rationale, not left implicit.
Source control and vascular access decisions
Antibiotics treat the bacteremia; they do not, by themselves, sterilize an infected catheter, and they cannot substitute for surgical or interventional correction of an infected fistula or graft. Source control is a parallel decision track that must run alongside, not after, antimicrobial selection.
The KDOQI (Kidney Disease Outcomes Quality Initiative) 2019 vascular access guideline update provides the current evidence-based framework for infection-related access decisions, including catheter exchange versus removal, salvage attempts with an antimicrobial lock, and monitoring for complications (Lok et al., 2020). Catheter salvage is never a universal default — the decision depends on the infecting organism (Staphylococcus aureus bacteremia, in particular, is a recognized indication favoring removal over salvage in most circumstances), whether the infection is uncomplicated or shows evidence of a persistent or complicated course, the patient's remaining access options, and hemodynamic stability. Complicated bacteremia — persistent positive cultures beyond 48–72 hours of appropriate therapy, or evidence of a metastatic focus such as endocarditis or septic emboli — should prompt catheter removal and, where locally available, echocardiography, rather than a continued salvage attempt.
Catheter locking solutions: prophylaxis versus treatment
A locking solution is instilled into the catheter lumen and left to dwell between sessions rather than infused into the bloodstream, so it acts locally on the catheter surface where biofilm forms. Plain heparin is the traditional interdialytic lock used for routine catheter patency and has no antimicrobial activity of its own. Two distinct uses of an antibiotic-containing lock — often built on a heparin base — should not be conflated, because they carry different stewardship weight.
For prophylaxis against a first or repeat CRBSI, KDOQI 2019 stops short of recommending a routine antibiotic lock for every catheter-dependent patient. It instead suggests selective use of a prophylactic antibiotic-heparin lock (for example, cefotaxime, gentamicin, or trimethoprim-sulfamethoxazole) or a non-antibiotic antimicrobial lock such as methylene blue, reserved for higher-risk patients — those with multiple prior CRBSIs — or for facilities with a persistently high CRBSI rate, explicitly to avoid the resistance-promoting effect of routine antibiotic exposure across an entire catheter-dependent population (Lok et al., 2020). A non-antibiotic lock (citrate- or taurolidine-based) is the more stewardship-consistent default for routine prophylaxis in lower-risk patients; an antibiotic-heparin lock is reserved for the selected higher-risk group the guideline describes, and its use should route through the same restricted-antibiotic approval process as any other antibiotic order.
For treatment, an antibiotic-heparin lock paired with systemic antibiotic therapy is the salvage-attempt regimen referenced above — its role is to help sterilize the catheter surface while systemic therapy treats the bacteremia, not to substitute for catheter removal when removal is otherwise indicated by organism, complication status, or persistent bacteremia. Either way, an antibiotic-containing lock is still a systemic antibiotic exposure for stewardship-tracking purposes, not a "topical" exception to oversight.
For arteriovenous fistula and graft infections, and for peritoneal access complications, the diagnostic and management detail is beyond this guide's stewardship scope; see this site's dedicated vascular access infection guide for the full clinical algorithm. This section exists to keep the source-control decision visible and jointly owned by nephrology, vascular access services, and the AMS team — not deferred until the antibiotic course is already finished.
Building the AMS and bloodstream-infection-prevention program
Reducing antibiotic demand starts upstream of any individual prescribing decision. The Centers for Disease Control and Prevention's (CDC) Core Elements framework for outpatient antibiotic stewardship — commitment, action for policy and practice, tracking and reporting, and education and expertise — gives dialysis-center leadership a structure to build a program around rather than relying on individual prescriber discipline alone (Sanchez et al., 2016). Layered on top of it, CDC's dialysis-specific Core Interventions target the bloodstream-infection side of the same problem directly (Centers for Disease Control and Prevention, 2024):
An antimicrobial stewardship program on top of this needs a named physician or pharmacist lead, a restricted/monitored antibiotic list with a defined approval pathway, and a routine (at minimum quarterly) review of antibiotic-start appropriateness, timeout completion, and BSI trends — feeding back to prescribers individually and to the unit in aggregate, never used to rank prescribers publicly without adequate case-mix adjustment and a confidential improvement process.
Philippine regulatory and surveillance context
Every element above sits inside a specific national policy and surveillance environment that a Philippine dialysis center's stewardship program should align to, and should cite by name and year rather than as generic "national guidelines."
The four Philippine policy and surveillance anchors a dialysis center's stewardship program should cite by name: the National Action Plan on Antimicrobial Resistance, the Department of Health (DOH) Antimicrobial Resistance Surveillance Program, the Philippine Health Insurance Corporation (PhilHealth) Circular No. 2024-0029, and a DOH Administrative Order.
- DOH
- Department of Health (Philippines)
- ARSP
- Antimicrobial Resistance Surveillance Program
- AMR
- Antimicrobial resistance
| Anchor | What it establishes | Stewardship-relevant use |
|---|---|---|
| Philippine National Action Plan on Antimicrobial Resistance 2024–2028 | The country's current One Health AMR strategy — stewardship, surveillance, infection prevention, awareness, and governance across human, animal, and environmental sectors. | The policy frame a center's own AMS charter should map to; not a bedside dosing reference. |
| DOH Antimicrobial Resistance Surveillance Program (ARSP) | The national reference for resistance trends among key pathogens, drawn from a sentinel-hospital network. | Use only as a labeled, year-stamped fallback when no valid facility-level antibiogram exists — never present a national figure as a substitute for local susceptibility data. |
| Philippine Health Insurance Corporation (PhilHealth) Circular No. 2024-0029 | Quality standards on the maintenance hemodialysis procedure. | Cross-check the center's infection-prevention and documentation practices against this circular's current requirements; verify for amendments before citing a specific provision. |
| DOH Administrative Order No. 2012-0001 | Licensure and regulation of dialysis clinics in the Philippines, including infection-control and patient-education requirements. | The regulatory floor for the unit's infection-prevention and quality-assurance obligations; confirm current amending issuances before relying on a specific clause. |
Evidence gaps worth naming explicitly
Published, dialysis-center-specific antibiotic-use and appropriateness data from the Philippines are limited; most of the surveillance evidence cited in this guide comes from United States NHSN reporting and should be read as a template for what to measure locally, not as a Philippine benchmark. National ARSP resistance estimates may not reflect a specific unit's patient population or specimen mix. Where local data do not yet exist, say so in the center's own stewardship documentation rather than substituting a foreign figure silently.
Clinical pearls
Pearl 1 — A positive culture is not automatically the diagnosis
A single set growing coagulase-negative staphylococci in an afebrile, hemodynamically stable patient is more likely a contaminant than true bacteremia. Correlate with the second culture set, the access exam, and the clinical trajectory before committing to a full treatment course — and repeat cultures rather than treating on an isolated, discordant result.
Pearl 2 — Missed sessions break dosing assumptions silently
A regimen timed to a thrice-weekly Monday/Wednesday/Friday schedule is invalidated by a rescheduled or skipped session. Confirm the actual last and next dialysis dates at every dosing decision rather than assuming the original schedule held.
Pearl 3 — The timeout is the intervention, not a formality
Programs that measure only "percentage of starts with an indication documented" miss the larger opportunity. The 48–72-hour narrowing/stop decision is where most of the achievable reduction in unnecessary antibiotic-days actually happens — track and report on timeout completion, not only on the initial order.
When to escalate beyond the unit
Persistent bacteremia beyond 48–72 hours of appropriate therapy, evidence of a metastatic focus, an organism or resistance pattern the unit's formulary cannot safely treat, or diagnostic uncertainty with no clear source after a full work-up should prompt infectious-disease or nephrology consultation and, where the required diagnostics or source control exceed the unit's capability, transfer — rather than an escalating empiric trial.
